UUID:DT6935FF-D§B4-46F1-B475-6F317ADBA094
TCGA-DX-AEBV-BlA-PR Redaﬁl‘ted

||||||||IllIIIIIIlllllllllllllIIIIIIIIIIIIIIIIIIIIIIII||||||
Illllllllll ll|l||l|Illllllllllllll||l|l|||l|||llIll||||l||l|
|||||||||||||||||||||||||||||||||||||||||||||||||||||I||||||

SURGICAL PATHOLOGY REPORT

 

Clinical Dingnaain & History:
Patient with newly diagnosed retroperitoneal sarcama.

Specimens Submitted:

1: Retroperitoneal sarcome

2: Pace: margin

3: Retroperitoneel tat

4: Retropsoaa margin

DIAGNOSIS:

1) SOFT TISSUE, RETROPERITONEAL, EXCISION:

- PLEOMORPHIC MYXOID SARCOMA. HIGH GRADE WITH EXTENSIVE NECROSIS, 14.5
CM GREATEST DIMENSION, INKED MARGINS FREE OF TUMOR (SEE COMMENT) .

2) PSOAS MARGIN. EXCISION:

- CHRONICALLY INFLAMED SKELETAL MUSCLE AND PIEROADIPOSE TISSUE WITH
REACTIVE KYOFIEROELASTIC PROLIFERATION. NO TUMOR SEEN.
3) PAT, RETEOPERITONEAL. EXCISION:

— FIBROADIPOSE TISSUE WITH ORGANIZING REMORRHAGE, CHRONIC INFLAMNATION
AND REACTIVE MOPIBROBLASTIC PROLIFERATION. NO TUMOR SEEN.
4) RETROPSOAS MARGIN. EXCISION:

- CHRONICLE-LY INFLAMED SKELETAL MUSCLE AND FIEROADIPOSE TISSUE WITH
REACTIVE MYOFIEROBLASTIC PROLIFERATION, NO TUMOR SEEN.

COMMENT: TUMOR CELLS ARE NEGATIVE FOR CYTOKERATIN (AE1/AE3

AND CAM 5.2) . DESMIN, SKA AND MYOGENIN. IN THIS LOCATION DEDIPFERENTIATED
LIPOSARCOMA IS POSSIBLE, HOWEVER, HISTOLOGIC SECTIONS DO NOT SHOW

RECOGNIZABLE WELL DIFFERENTIATED LIPOSARCOMA. HIGH GRADE MYXOPIBROSARCONA
SHOULD ALSO BE CONSIDERED.

I ATTEST THAT THE ABOVE DIAGNOSIS IS BASED UPON HY PERSONAL EXAMINATION 0?

THE SLIDES (AND/OR OTHER MATERIAL) I AND THAT I HAVE REVIEWED AND APPROVED
THIS REPORT.

.,. Report Electronically Signed Out ***

*' Continued on next page *'

6% :C3D{>«3
- AW SSH/5

X? w 4 QWM; 3302/3
5,113 me C4171)
Cszl/zz/I’é

SURGICAL PATHOLOGY REPORT

------------------------------------------------------------ Page 2 of 3
Special studies :

Result Special Stain Consent

AEI:A33

des

MYOGENIN

SMA

can 5.2

NEG CONT

IMH RECUT

Gross Description:

1) The specimen is received fresh labeled. "Retroperitonesl sarcoma".
The specimen consists of a unorisnted segment of encapsulated dense fatty
tissue measuring 14.5 x 13.5 x 5.5 cm and weighing 1630 grams. The external
capsule is inked in black. The specimen is sectioned to reveal
multilohulated, fleshy, gelatinous, glistening cut surfaces with diffuse
areas of hemorrhage. There are also solid whitish tan areas measuring from
0.3 to 4.5 cm in greatest dimension. Portion of the specimen is been
submitted for TPS, electron microscopy and special studies. Representative
sections submitted.

Summary of sections:
U-representative section of the variegated cut surface.

2) The specimen is received in. formalin and labeled, 'PSOAS margin". It
consists of two pieces of tan red soft tissue. measuring 3.0 x 1.5 x 0.5 and
3.4 x 1.4 x 0.5 cm. The specimen is not oriented. The entire specimen is
submitted.

Summary of section:
M—marg‘in.

3) The specimen is received in formalin and labeled. 'Retroperitoneal
fat". It consists of an irregular piece of tan yellow lobulated soft
tissue. measuring 6 x 4 x 3 cm. Sections show two possible lymph nodes
measuring up to 0.2 cm. Representative sections are submitted.

Summary of. sections:
LN—lymph nodes?

4) The specimen is received in formalin and labeled, "Retro PSOAS

** Continued on next page *'

SUKGLW PATHOLOGY REPORT E

------------------------------------------------------------ Page 3 of 3
margin“. It consists of an irregular piece of tan-red membranous soft
tissue, measuring 9 x 6 x 1.2 cm. Sections show tan-red surfaces with focal
hemorrhagic areas. The surface is inked black. The entire specimen is
submitted.

Summary of sections:
M-margin.

Summary of Sections:
Part 1: SP: Retroperitoneal sarcoma

Block Sect. Site PCs
14 u 14

Part 2: SP: Psoes margin

Block Sect. Site PCs
4 m 4

Part 3: SP: Retroperitoneal fat

Block Sect. Site PCs
7 ln 7

Part 4: SP: Retropsoas margin

Block Sect. Site PCs
23 m 23

** End of Report *'

PM) Tss—dx Maura-v01 W 96"”
TCGR 'htw‘n #1 be myxc-Frwfm.

 

 

 

 

  
   
 

 

 

 

 

 

1
5mm _ A.) ,ILLIJH. m , J10 '
Bag-Ions Sucrsnancy/ I v, I
franarLTE-ﬂrr Eﬂrigmry 3/ "4
3; ~— . . ‘ V _f

 

 

 

L'V _. _ ._.
Elm.” r / umqumlbsso _ -_.
I

Fﬁl‘l‘k Ust:Re£Jyel“g:1/él ‘ 3

 
 

 

 

 

TCGA Pathologlc Diagnosis Discrepancy Form

V4.00

 

 

 

 

 

1 "mm a his: The TcaA‘Patha'IogicDiagnosis Discrep

obey Form should be compieteci when the pathologic diagnosis .
documented on the initial pathoiogy report for‘a 'case submitted for TCGA is inconsistent with the :1!ng provided on the
Case Quality Control Fern: Completedfbr the submitted case.

 

 

 

 

 

 

 

 

Tissue Source Site ('l‘SS): - TSS Identifier: TSS Unique Patient Identiﬁer:
Completed By (Interviewer Name on Opanlinica): _ Completed Date: .
\ 5
[Diagnosis Ihfdrmatlhn _ ~ -' . ., .p ‘.
# Data Element Entry Alternatives Worlggg instructions
Provide the diagnosis] hlsnoiogic subtypeijs) documented on
Pathologic Diagnosis ?/ A“ - 1;" the Initial pathology report for this case. lithe histology for
1 Provided an Initial <30 W this case is mixed. provide all ﬁshed subtypes.
Pathology Report
Histolo gic features of ‘. Provide the histologic faamres selected on the TCGA Case
2 the sample provided a? 0 £5 I'M: Quality Control Form completed for this case.
for TCGA, as reﬂected
on the CQCF.

 

 

 

[Discrepancyhetwoen PathologyReportand Case Quality Control ram..,-. . . . . . = - V -

 

Provide a reason describing why the diagnosis on the initial

 

 

 

 

 

3 Egggigggaiecaywn for 72‘ 54" W?” “I”? «a ﬁdu— If; pMologyreportforuusmeisnotconslmsntwnh the
between the pathology £9, .. Z 2/ diagnosisselectcd onﬁxsTCGACaseQuaMtyConu-ol Form.
reportand the TCGA 6%3‘”? ”'4'” of
Case QualityConrrol 669e— # an ,— 1 g tug/97¢ ”4%“ g i 5L
Form. V ‘ _

elf/M ﬂywﬂo-Je/AL me aﬂumgeo’ vﬂu .o a.
Ark 74% [Amy/Au WK 0! SMCOM ﬂ/vﬁofé a W
WM Mao afar/id Z3 Who-r aé'yW. o
. #- , ~
in; W .o Mimi w~ tax/L @X.ﬁgm...¢.m,
47:1. freeze.
Name of TSS Reviewing Provide the name ofrhe pathologist who reviewed this case
4 Pathologist or ‘ for'i‘CGA.
Bioreposltory Director

 

 

 

 

i acknowledge that the above information provided by my Institution is true and com and has been quality controlled.

 

TSS Reviewing Pathologist or Biorepository Director

 

Date

I acknowledge that the above Information provided W institution is true and correct and has been quoiiv controlled. The Attending Pathologist or the
M

anal-IMO.“ “III-ml

Principal LnVustigator Signature

ham informed or is aware unite above discrepancy in diagnoses.

 

Date

